Matthew W. Tikonoff
Mergers & Acquisitions
- Syncona Limited (LON: SYNC) in its acquisition of Applied Genetic Technologies Corporation (Nasdaq: AGTC)
- HouseWorks, a home health care provider, in connection with a majority equity investment by InTandem Capital Partners
- Philips Healthcare in connection with numerous mergers and acquisitions and other strategic transactions. Representative transactions include:
- Divestiture of Philips’ Aging and Caregiving (ACG) business
- Acquisition of Vesper Medical, Inc., a medical technology company that develops minimally-invasive peripheral vascular devices
- Acquisition of Intact Vascular, the maker of the Tack specialized implantable device for treating peripheral artery disease
- Acquisition of the teleradiology platform of Direct Radiology
- Acquisition of EPD Solutions, the innovator of a breakthrough cardiac imaging and navigation system
- Acquisition of Remote Diagnostics Technologies, a UK-based innovator of advanced solutions for the pre-hospital market providing monitoring, cardiac therapy and data management
- Acquisition of Blue Willow Systems, a cloud-based senior living community resident safety platform
- Acquisition of CardioProlific, a company developing catheter-based thrombectomy approaches to peripheral vascular disease
- Netsmart Technologies, a leading provider of healthcare Software as a Service (SaaS) technology and services solutions, in connection with numerous merger and acquisitions. Representative transactions include:
- Acquisition of Remarkable Health, an industry-leading provider of artificial intelligence technology and software solutions for behavioral health, substance use and human services organizations
- Acquisition of the entity owning TheraOffice, an industry-leading practice management platform for physical therapy and rehabilitation practices
- Acquisition of SimpleLTC, a data analytics and consulting services firm
- Acquisition of GPM, a Software-as-a-Service technology and services company
- Acquisition of Tellus, a provider of electronic visit verification (EVV), mobile care delivery and claims processing technology
- Acquisition of Quality In Real Time (QIRT), a post-acute health care consulting firm
- Acquisition of McBee Associates, a healthcare consulting firm
- Acquisition of Homecare Accounting Solutions, LLC, a cloud-based software company for home care agencies
- Acquisition of Devero, Inc., a healthcare technology company specializing in home healthcare and hospice
- Acquisition of HealthMEDX, a developer of electronic medical record (EMR) solutions
- Acquisition of Trend Consulting Services, a provider of information technology outsourcing and infrastructure support services
- Acquisition of Lavender & Wyatt Systems, a provider of enterprise behavioral health electronic medical records software and technology solutions
- Viela Bio (Nasdaq:VIE) in its $3.05 billion sale to Horizon Therapeutics (Nasdaq: HZNP), ranked in Fierce Biotech’s “The Top 10 Biopharma M&A Deals in 2021”
- F-Star Therapeutics in its reverse merger with Spring Bank Pharmaceuticals (Nasdaq: SBPH)
- Cheetah Medical, a provider of noninvasive hemodynamic monitoring devices, in connection with its sale to Baxter International Inc. (NYSE:BAX)
- Patriot Energy Group, a retail electricity and natural gas management firm, in its strategic alliance with EMEX, LLC
- Belmont Instrument Corporation, a leading provider of fluid warming infusion systems, in its recapitalization transaction with Audax Private Equity
- Jacqueline's Wholesale Bakery, Inc., a leading manufacturer of frozen cookie dough for the in-store bakery and foodservice channels, in connection with its sale to Rich Product Corporation
- Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
- Associated Home Care, a private-duty home health aide provider, in its sale to Amedisys (NASDAQ: AMED)
- Frazier Healthcare Ventures, a middle-market private equity firm, in its acquisition of a medical footware company
- SiOnyx, an image sensor and camera company specializing in low light and near infrared imaging, in its acquisition by a leading private equity firm and subsequent sale to DC Capital Partners
- Edgile, a cybersecurity consulting firm, in a minority investment transaction with a leading private equity firm
- A privately-held distributor of industrial supplies in its sale to a strategic competitor
- Essilor International, an eyewear company, in its acquisition of Costa (NASDAQ: ATX)
- FGX International, an eyewear company, in its acquisition of Stylemark
- Dynasil Corporation of America (NASDAQ: DYSL) in the sale of its cancer medical probe business to Dilon Technologies and the sale of its x-ray fluorescence lead paint detector business to Protec
- PTC (NASDAQ: PTC) in its acquisition of Enigma Information Systems
- Ampersand Capital Partners in its acquisitions of numerous portfolio companies
- Syncona Ltd. (LSE: SYNC) in its acquisition of Freeline Therapeutics (Nasdaq: FRLN)
- Standard BioTools (Nasdaq: LAB) in its stock-for-stock merger with SomaLogic (Nasdaq: SLGC)
Securities Offerings
- Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $75 million follow-on offering and its $10 million registered direct offering
- Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $83.6 million initial public offering
- WAVE Life Sciences (NASDAQ: WVE) in its $102 million initial public offering
- Lamar Advertising Company (NASDAQ: LAMR) in Rule 144A debt offerings and follow-on exchange offers
- Stemline Therapeutics (NASDAQ: STML) in its $30 million initial public offering

Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.

Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.

In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.